{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T04:38:58Z","timestamp":1783226338766,"version":"3.54.6"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:00:00Z","timestamp":1675468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:00:00Z","timestamp":1675468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod Biol Endocrinol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>While anti-M\u00fcllerian hormone (AMH) predicts quantitative IVF outcomes such as oocyte yield, it is not certain whether AMH predicts markers of oocyte quality such as aneuploidy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective case\u2013control analysis of the SART-CORS database, 2014\u20132016, to determine whether anti-M\u00fcllerian hormone (AMH) predicts aneuploidy and live birth in IVF cycles utilizing preimplantation genetic testing for aneuploidy (PGT-A).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 51,273 cycles utilizing PGT-A for all embryos, 10,878 cycles were included in the final analysis; of these, 2,100 cycles resulted in canceled transfer due to lack of normal embryos and 8,778 cycles resulted in primary FET. AMH levels of cycles with\u2009\u2265\u20091 euploid embryo were greater than those of cycles with no normal embryos, stratifying by number of embryos biopsied (1\u20132, 3\u20134, 5\u20136, and\u2009\u2265\u20097), <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.017 for each stratum. Adjusting for age and number of embryos biopsied, AMH was a significant independent predictor of\u2009\u2265\u20091 euploid embryo for all age groups:\u2009&lt;\u200935 yrs (aOR 1.074; 95%CI 1.005\u20131.163), 35\u201337\u00a0years (aOR 1.085; 95%CI 1.018\u20131.165) and\u2009\u2265\u200938\u00a0years (aOR 1.055; 95%CI 1.020\u20131.093). In comparative model analysis, AMH was superior to age as a predictor of\u2009\u00a0\u2265\u20091 euploid embryo for age groups\u2009&lt;\u200935\u00a0years and 35\u201337\u00a0years, but not\u2009\u00a0\u2265\u200938\u00a0years. Across all cycles, age (aOR 0.945, 95% CI 0.935\u20130.956) and number of embryos (aOR 1.144, 95%CI 1.127\u20131.162) were associated with live birth per transfer, but AMH was not (aOR 0.995, 95%CI 0.983\u20131.008). In the subset of cycles resulting in\u2009\u2265\u20091 euploid embryo for transfer, neither age nor AMH were associated with live birth.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Adjusting for age and number of embryos biopsied, AMH independently predicted likelihood of obtaining\u2009\u2265\u20091 euploid embryo for transfer in IVF PGT-A cycles. However, neither age nor AMH were predictive of live birth once a euploid embryo was identified by PGT-A for transfer. This analysis suggests a predictive role of AMH for oocyte quality (aneuploidy risk), but not live birth per transfer once a euploid embryo is identified following PGT-A.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12958-023-01066-w","type":"journal-article","created":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T05:09:49Z","timestamp":1675487389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["AMH independently predicts aneuploidy but not live birth per transfer in IVF PGT-A cycles"],"prefix":"10.1186","volume":"21","author":[{"given":"Howard J.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Seifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshef","family":"Tal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,4]]},"reference":[{"key":"1066_CR1","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0015-0282(01)03201-0","volume":"77","author":"DB Seifer","year":"2002","unstructured":"Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM. Early follicular serum m\u00fcllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril. 2002;77:468\u201371.","journal-title":"Fertil Steril"},{"key":"1066_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/humupd\/dmp036","volume":"16","author":"A La Marca","year":"2010","unstructured":"La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16:113\u201330.","journal-title":"Hum Reprod Update"},{"key":"1066_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ajog.2017.02.027","volume":"217","author":"R Tal","year":"2017","unstructured":"Tal R, Seifer DB. Ovarian reserve testing: a user\u2019s guide. Am J Obstet Gynecol. 2017;217:129\u201340.","journal-title":"Am J Obstet Gynecol"},{"key":"1066_CR4","unstructured":"Practice Committee of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org, Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020;114:1151\u20137."},{"key":"1066_CR5","doi-asserted-by":"crossref","unstructured":"Borges E, Braga DPAF, Setti A, Figueira R de C, Iaconelli A. The predictive value of serum concentrations of anti-M\u00fcllerian hormone for oocyte quality, fertilization, and implantation. JBRA Assist Reprod. 2017;21:176\u201382.","DOI":"10.5935\/1518-0557.20170035"},{"key":"1066_CR6","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s11596-018-1954-6","volume":"38","author":"X-L Li","year":"2018","unstructured":"Li X-L, Huang R, Fang C, Liang X-Y. Basal Serum Anti-M\u00fcllerian Hormone Level as a Predictor of Clinical Outcomes in Freezing-all Embryo Transfer Program. Curr Med Sci. 2018;38:861\u20137.","journal-title":"Curr Med Sci"},{"key":"1066_CR7","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1210\/clinem\/dgab168","volume":"106","author":"R Tal","year":"2021","unstructured":"Tal R, Seifer DB, Tal R, Granger E, Wantman E, Tal O. AMH Highly Correlates With Cumulative Live Birth Rate in Women with Diminished Ovarian Reserve Independent of Age. J Clin Endocrinol Metab. 2021;106:2754\u201366.","journal-title":"J Clin Endocrinol Metab"},{"key":"1066_CR8","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/humupd\/dmu003","volume":"20","author":"S Iliodromiti","year":"2014","unstructured":"Iliodromiti S, Kelsey TW, Wu O, Anderson RA, Nelson SM. The predictive accuracy of anti-M\u00fcllerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature. Hum Reprod Update. 2014;20:560\u201370.","journal-title":"Hum Reprod Update"},{"key":"1066_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.fertnstert.2014.09.041","volume":"103","author":"R Tal","year":"2015","unstructured":"Tal R, Tal O, Seifer BJ, Seifer DB. Antim\u00fcllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis. Fertil Steril. 2015;103:119-130.e3.","journal-title":"Fertil Steril"},{"key":"1066_CR10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.fertnstert.2015.10.004","volume":"105","author":"DB Seifer","year":"2016","unstructured":"Seifer DB, Tal O, Wantman E, Edul P, Baker VL. Prognostic indicators of assisted reproduction technology outcomes of cycles with ultralow serum antim\u00fcllerian hormone: a multivariate analysis of over 5,000 autologous cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012\u20132013. Fertil Steril. 2016;105:385-393.e3.","journal-title":"Fertil Steril"},{"key":"1066_CR11","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.fertnstert.2021.01.020","volume":"115","author":"DB Seifer","year":"2021","unstructured":"Seifer DB. Connecting the dots between oocyte quantity and quality in diminished ovarian reserve. Fertil Steril. 2021;115:890.","journal-title":"Fertil Steril"},{"issue":"59","key":"1066_CR12","first-page":"e1","volume":"211","author":"R Tal","year":"2014","unstructured":"Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antim\u00fcllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Am J Obstet Gynecol. 2014;211(59):e1-8.","journal-title":"Am J Obstet Gynecol"},{"key":"1066_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/humrep\/des356","volume":"28","author":"JG Bentzen","year":"2013","unstructured":"Bentzen JG, Forman JL, Larsen EC, Pinborg A, Johannsen TH, Schmidt L, et al. Maternal menopause as a predictor of anti-Mullerian hormone level and antral follicle count in daughters during reproductive age. Hum Reprod. 2013;28:247\u201355.","journal-title":"Hum Reprod"},{"key":"1066_CR14","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/humrep\/det446","volume":"29","author":"M D\u00f3lleman","year":"2014","unstructured":"D\u00f3lleman M, Depmann M, Eijkemans MJC, Heimensem J, Broer SL, van der Stroom EM, et al. Anti-Mullerian hormone is a more accurate predictor of individual time to menopause than mother\u2019s age at menopause. Hum Reprod. 2014;29:584\u201391.","journal-title":"Hum Reprod"},{"key":"1066_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/GCO.0000000000000623","volume":"32","author":"A Kotlyar","year":"2020","unstructured":"Kotlyar A, Seifer DB. Anti-M\u00fcllerian hormone as a qualitative marker - or just quantity? Curr Opin Obstet Gynecol. 2020;32:219\u201326.","journal-title":"Curr Opin Obstet Gynecol"},{"key":"1066_CR16","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/GRF.0000000000000436","volume":"62","author":"E Granger","year":"2019","unstructured":"Granger E, Tal R. Anti-M\u00fcllerian Hormone and Its Predictive Utility in Assisted Reproductive Technologies Outcomes. Clin Obstet Gynecol. 2019;62:238\u201356.","journal-title":"Clin Obstet Gynecol"},{"key":"1066_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/humupd\/dmi006","volume":"11","author":"DT Baird","year":"2005","unstructured":"Baird DT, Collins J, Egozcue J, Evers LH, Gianaroli L, Leridon H, et al. Fertility and ageing. Hum Reprod Update. 2005;11:261\u201376.","journal-title":"Hum Reprod Update"},{"key":"1066_CR18","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1210\/er.2009-0006","volume":"30","author":"FJ Broekmans","year":"2009","unstructured":"Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev. 2009;30:465\u201393.","journal-title":"Endocr Rev"},{"key":"1066_CR19","doi-asserted-by":"crossref","unstructured":"De Conto E, Genro VK, da Silva DS, Chapon R de CB, Cunha-Filho JSL. AMH as a Prognostic Factor for Blastocyst Development. JBRA Assist Reprod. 2015;19:131\u20134.","DOI":"10.5935\/1518-0557.20150029"},{"key":"1066_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ejogrb.2010.02.029","volume":"150","author":"K Majumder","year":"2010","unstructured":"Majumder K, Gelbaya TA, Laing I, Nardo LG. The use of anti-M\u00fcllerian hormone and antral follicle count to predict the potential of oocytes and embryos. Eur J Obstet Gynecol Reprod Biol. 2010;150:166\u201370.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1066_CR21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.fertnstert.2006.06.019","volume":"87","author":"JMJ Smeenk","year":"2007","unstructured":"Smeenk JMJ, Sweep FCGJ, Zielhuis GA, Kremer JAM, Thomas CMG, Braat DDM. Antim\u00fcllerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. Fertil Steril. 2007;87:223\u20136.","journal-title":"Fertil Steril"},{"key":"1066_CR22","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1093\/humrep\/dey238","volume":"33","author":"SJ Morin","year":"2018","unstructured":"Morin SJ, Patounakis G, Juneau CR, Neal SA, Scott RT, Seli E. Diminished ovarian reserve and poor response to stimulation in patients <38 years old: a quantitative but not qualitative reduction in performance. Hum Reprod. 2018;33:1489\u201398.","journal-title":"Hum Reprod"},{"key":"1066_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.fertnstert.2007.06.063","volume":"90","author":"M-Y Thum","year":"2008","unstructured":"Thum M-Y, Abdalla HI, Taylor D. Relationship between women\u2019s age and basal follicle-stimulating hormone levels with aneuploidy risk in in vitro fertilization treatment. Fertil Steril. 2008;90:315\u201321.","journal-title":"Fertil Steril"},{"key":"1066_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/humrep\/dei270","volume":"21","author":"T Silberstein","year":"2006","unstructured":"Silberstein T, MacLaughlin DT, Shai I, Trimarchi JR, Lambert-Messerlian G, Seifer DB, et al. Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Hum Reprod. 2006;21:159\u201363.","journal-title":"Hum Reprod"},{"key":"1066_CR25","doi-asserted-by":"publisher","first-page":"532","DOI":"10.5468\/ogs.20168","volume":"64","author":"VM Scantamburlo","year":"2021","unstructured":"Scantamburlo VM, von Linsingen R, Centa LJR, Toso KFD, Scaraboto D, Araujo J\u00fanior E, et al. Association between decreased ovarian reserve and poor oocyte quality. Obstet Gynecol Sci. 2021;64:532\u20139.","journal-title":"Obstet Gynecol Sci"},{"key":"1066_CR26","first-page":"50","volume":"26","author":"HSG Morales","year":"2022","unstructured":"Morales HSG, L\u00f3pez GGP, Cort\u00e9s DV, Torres GCR, Hern\u00e1ndez HS, Guiot ML, et al. Evaluation of the Anti-M\u00fcllerian Hormone and its Association with Embryo Quality in Advanced Reproductive Treatments in a Latin American Population. JBRA Assist Reprod. 2022;26:50\u20132.","journal-title":"JBRA Assist Reprod"},{"key":"1066_CR27","doi-asserted-by":"publisher","first-page":"4224417","DOI":"10.1155\/2022\/4224417","volume":"2022","author":"T-C Sun","year":"2022","unstructured":"Sun T-C, Chen X, Shi C, Tian L, Zhou S-J. The Predictive Levels of Serum Anti-M\u00fcllerian Hormone and the Combined Index of the Number of Retrieved Oocytes and Good-Quality Embryos in Advanced-Age Infertile Women. Int J Endocrinol. 2022;2022:4224417.","journal-title":"Int J Endocrinol"},{"key":"1066_CR28","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1007\/s10815-021-02227-9","volume":"38","author":"M Simopoulou","year":"2021","unstructured":"Simopoulou M, Sfakianoudis K, Maziotis E, Tsioulou P, Grigoriadis S, Rapani A, et al. PGT-A: who and when? \u0391 systematic review and network meta-analysis of RCTs. J Assist Reprod Genet. 2021;38:1939\u201357.","journal-title":"J Assist Reprod Genet"},{"key":"1066_CR29","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/AOG.0000000000004712","volume":"139","author":"BS Bedrick","year":"2022","unstructured":"Bedrick BS, Tipping AD, Nickel KB, Riley JK, Jain T, Jungheim ES. State-Mandated Insurance Coverage and Preimplantation Genetic Testing in the United States. Obstet Gynecol. 2022;139:500\u20138.","journal-title":"Obstet Gynecol"},{"key":"1066_CR30","doi-asserted-by":"publisher","first-page":"55.e1","DOI":"10.1016\/j.ajog.2021.01.021","volume":"225","author":"M Lee","year":"2021","unstructured":"Lee M, Lofgren KT, Thomas A, Lanes A, Goldman R, Ginsburg ES, et al. The cost-effectiveness of preimplantation genetic testing for aneuploidy in the United States: an analysis of cost and birth outcomes from 158,665 in vitro fertilization cycles. Am J Obstet Gynecol. 2021;225:55.e1-55.e17.","journal-title":"Am J Obstet Gynecol"},{"key":"1066_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/AOG.0b013e318278eeda","volume":"121","author":"MG Katz-Jaffe","year":"2013","unstructured":"Katz-Jaffe MG, Surrey ES, Minjarez DA, Gustofson RL, Stevens JM, Schoolcraft WB. Association of abnormal ovarian reserve parameters with a higher incidence of aneuploid blastocysts. Obstet Gynecol. 2013;121:71\u20137.","journal-title":"Obstet Gynecol"},{"key":"1066_CR32","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.fertnstert.2020.10.051","volume":"115","author":"EG Jaswa","year":"2021","unstructured":"Jaswa EG, McCulloch CE, Simbulan R, Cedars MI, Rosen MP. Diminished ovarian reserve is associated with reduced euploid rates via preimplantation genetic testing for aneuploidy independently from age: evidence for concomitant reduction in oocyte quality with quantity. Fertil Steril. 2021;115:966\u201373.","journal-title":"Fertil Steril"},{"key":"1066_CR33","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.fertnstert.2022.06.008","volume":"118","author":"Y Fouks","year":"2022","unstructured":"Fouks Y, Penzias A, Neuhausser W, Vaughan D, Sakkas D. A diagnosis of diminished ovarian reserve does not impact embryo aneuploidy or live birth rates compared to patients with normal ovarian reserve. Fertil Steril. 2022;118:504\u201312.","journal-title":"Fertil Steril"},{"key":"1066_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12958-020-00616-w","volume":"18","author":"N Gleicher","year":"2020","unstructured":"Gleicher N, Albertini DF, Barad DH, Homer H, Modi D, Murtinger M, et al. The 2019 PGDIS position statement on transfer of mosaic embryos within a context of new information on PGT-A. Reprod Biol Endocrinol. 2020;18:57.","journal-title":"Reprod Biol Endocrinol"},{"key":"1066_CR35","doi-asserted-by":"crossref","unstructured":"Practice Committee and Genetic Counseling Professional Group (GCPG) of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org. Clinical management of mosaic results from preimplantation genetic testing for aneuploidy (PGT-A) of blastocysts: a committee opinion. Fertil Steril. 2020;114:246\u201354.","DOI":"10.1016\/j.fertnstert.2020.05.014"},{"key":"1066_CR36","doi-asserted-by":"publisher","first-page":"602.e1","DOI":"10.1016\/j.ajog.2018.09.030","volume":"219","author":"TG Kim","year":"2018","unstructured":"Kim TG, Neblett MF, Shandley LM, Omurtag K, Hipp HS, Kawwass JF. National mosaic embryo transfer practices: a survey. Am J Obstet Gynecol. 2018;219:602.e1-602.e7.","journal-title":"Am J Obstet Gynecol"},{"key":"1066_CR37","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3390\/jcm10071369","volume":"10","author":"S Abhari","year":"2021","unstructured":"Abhari S, Kawwass JF. Pregnancy and Neonatal Outcomes after Transfer of Mosaic Embryos: A Review. J Clin Med. 2021;10:1369.","journal-title":"J Clin Med"},{"key":"1066_CR38","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/pd.5840","volume":"41","author":"H Cuckle","year":"2021","unstructured":"Cuckle H, Morris J. Maternal age in the epidemiology of common autosomal trisomies. Prenat Diagn. 2021;41:573\u201383.","journal-title":"Prenat Diagn"},{"key":"1066_CR39","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.fertnstert.2017.10.021","volume":"109","author":"R Tal","year":"2018","unstructured":"Tal R, Seifer DB, Wantman E, Baker V, Tal O. Antim\u00fcllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012\u20132013. Fertil Steril. 2018;109:258\u201365.","journal-title":"Fertil Steril"},{"key":"1066_CR40","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.fertnstert.2017.03.011","volume":"107","author":"C Rubio","year":"2017","unstructured":"Rubio C, Bellver J, Rodrigo L, Castill\u00f3n G, Guill\u00e9n A, Vidal C, et al. In vitro fertilization with preimplantation genetic diagnosis for aneuploidies in advanced maternal age: a randomized, controlled study. Fertil Steril. 2017;107:1122\u20139.","journal-title":"Fertil Steril"},{"key":"1066_CR41","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1093\/humrep\/dev159","volume":"30","author":"FM Ubaldi","year":"2015","unstructured":"Ubaldi FM, Capalbo A, Colamaria S, Ferrero S, Maggiulli R, Vajta G, et al. Reduction of multiple pregnancies in the advanced maternal age population after implementation of an elective single embryo transfer policy coupled with enhanced embryo selection: pre- and post-intervention study. Hum Reprod. 2015;30:2097\u2013106.","journal-title":"Hum Reprod"}],"container-title":["Reproductive Biology and Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-023-01066-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12958-023-01066-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-023-01066-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T05:12:58Z","timestamp":1675487578000},"score":1,"resource":{"primary":{"URL":"https:\/\/rbej.biomedcentral.com\/articles\/10.1186\/s12958-023-01066-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,4]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1066"],"URL":"https:\/\/doi.org\/10.1186\/s12958-023-01066-w","relation":{},"ISSN":["1477-7827"],"issn-type":[{"value":"1477-7827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,4]]},"assertion":[{"value":"1 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the SART research committee and exempted from review by the Yale School of Medicine IRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DBS receives royalties from license between Rutgers Medical School and MGH with Beckman Coulter for patent of AMH for determining ovarian reserve.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}